ClinicalTrials.gg
RecruitingNCT07298889Updated Jan 7, 2026

High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS

An interventional study of The level of PEEP during noninvasive ventilation in Noninvasive Ventilation, Pneumonia and ARDS, sponsored by Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Chongqing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
706
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Pneumonia with a site in China — 44 open to participants now, 48 under way, 2 of them phase 3. Pneumonia · China.

Planned enrollment
15th of 94
706 · median 154
Started
2026
with 12 others
No phase
36 of 142
14 open now
Primary completion
2029-12
later than 47 of 47 live
Registered
128th of 142
by date

Among the 142 studies in Pneumonia with a site in China, this one is the 15th largest by planned enrollment of the 94 interventional ones that give a count, is one of 13 that started in 2026, is one of 36 with no phase, reaches primary completion later than 47 of the 47 other live ones, and was the 128th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

44 of the 142 studies in Pneumonia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Pneumonia with a site in China, or all of them as a file.
02

Study summary

Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.

03

Conditions studied

  • Noninvasive Ventilation
  • Pneumonia
  • ARDS

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • PaO2/FiO2 ≤300 mmHg or SpO2/FiO2 ≤315(SpO2 ≤97%)
  • Anticipated NIV duration > 12 h
  • Preserved consciousness (GCS≥13)

Exclusion criteria

Exclusion Criteria:

  • Use of NIV > 24 h before randomization
  • Acute-on-chronic respiratory failure
  • Congestive heart failure
  • Use of NIV after extubation (within 48 hours)
  • to NIV (e.g., anatomical malformations, recent pulmonary/esophageal surgery [within 7 days])
  • Pneumothorax
  • NIV intolerance
  • Refusal to participate
  • Pregnancy
  • Need for emergency intubation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
706 participants (estimated)

Study arms

  • Experimental
    High PEEP group

    Patients in high PEEP group will received 10 to 15 cmH2O of PEEP during noninvasive ventilation.

    Procedure: The level of PEEP during noninvasive ventilation

  • Active comparator
    Low PEEP group

    Patients in low PEEP group will received 5 cmH2O of PEEP during noninvasive ventilation.

    Procedure: The level of PEEP during noninvasive ventilation

Interventions

  • ProcedureThe level of PEEP during noninvasive ventilation

    In patients receiving noninvasive ventilation, participants will be randomly assigned to either a low or a high PEEP group. In the high PEEP group, PEEP will be set between 10 and 15 cmH2O. In the low PEEP group, PEEP will be maintained at 5 cmH2O.

06

What researchers measure

Primary outcomes

  1. 28-day intubation-free survival

    Time frame: from randomization to 28 days after randomization

Secondary outcomes

  1. 28-day intubation rate

    Time frame: from randomization to 28 days after randomization

  2. the need for intubation within 28 days

    The rate of the need for intubation within 28 days after randomization was assessed by two independent reviewers with extensive critical care experience.

    Time frame: from randomization to 28 days after randomization

  3. 28-day survival

    Time frame: from randomization to 28 days after randomization

  4. 7-category ordinal scale for clinical improvement at 28 days

    The 7-category ordinal scale is as follows: 1 = not hospitalized and has resumed normal activities; 2 = not hospitalized but unable to resume normal activities; 3 = hospitalized without requiring supplemental oxygen; 4 = hospitalized and requiring supplemental oxygen; 5 = hospitalized and requiring HFNC, NIV, or both; 6 = hospitalized and requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; 7 = death.

    Time frame: from randomization to 28 days after randomization

  5. 28-day invasive ventilator-free days

    Time frame: from randomization to 28 days after randomization

  6. 28-day noninvasive ventilator days

    Time frame: from randomization to 28 days after randomization

  7. Length of ICU stay

    Time frame: up to 24 weeks

  8. Length of hospital stay

    Time frame: up to 24 weeks

  9. ICU mortality

    Time frame: up to 24 weeks

  10. Hospital mortality

    Time frame: up to 24 weeks

  11. 60-day mortality

    Time frame: from randomization to 60 days after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — These study data contain ethnic demographic information. Since it remains unclear whether Chinese laws permit the public disclosure of such data upon the completion of the research, a decision has been made to temporarily withhold data sharing during the study design phase.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 47 months is above that.

Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 23, 2025
StartActual
Jan 4, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298889
Lead sponsor
Chongqing Medical University
Responsible party
Duan jun (attending physician, First Affiliated Hospital of Chongqing Medical University) — Principal investigator
First posted
Dec 23, 2025
Start date
Jan 4, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jan 7, 2026

Study contacts

Mengyi Ma
Contact
1062914316@qq.com
86-023-89012680

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion